Cassava Sciences Inc  (SAVA)
Other Ticker:  
Price: $23.0000 $0.02 0.087%
Day's High: $23.2824 Week Perf: 4.93 %
Day's Low: $ 22.81 30 Day Perf: -3.97 %
Volume (M): 382 52 Wk High: $ 32.10
Volume (M$): $ 8,775 52 Wk Avg: $22.35
Open: $23.00 52 Wk Low: $12.32

 Market Capitalization (Millions $) 964
 Shares Outstanding (Millions) 42
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -97
 Cash Flow (TTM) (Millions $) -80
 Capital Exp. (TTM) (Millions $) 1

Cassava Sciences Inc
Cassava Sciences Inc is a biopharmaceutical company that focuses on developing drugs for the treatment of Alzheimer's disease. The company's primary drug candidate is called PTI-125, which aims to reduce neuroinflammation and improve cognition in Alzheimer's patients. Cassava Sciences also has an extensive pipeline of other candidates targeting various aspects of the disease. The company is dedicated to advancing innovative, science-driven solutions for Alzheimer's, a debilitating neurodegenerative disease that affects millions of people worldwide.

   Company Address: 6801 N. Capital of Texas Highway, Building 1; Suite 300 Austin 78731 TX
   Company Phone Number: 501-2444   Stock Exchange / Ticker: NASDAQ SAVA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Cassava Sciences Inc

Cassava Sciences Reports Operating Deficit in Fourth Quarter of 2023

In a recent financial report, Cassava Sciences, Inc. (Nasdaq: SAVA) disclosed its full-year financial and operating results for the year ended December 31, 2023. The biotechnology company, which focuses on developing treatments for Alzheimer's disease and other neurodegenerative disorders, reported an operating deficit of $-22.789 million for the fourth quarter of 2023, with no revenue disclosed thus far.
Despite the challenges faced by Cassava Sciences, its stock performance has been on a downward trend. The company's stock dropped by -8.01% in February, bringing the year-to-date performance to -2.19%. Additionally, the stock is currently trading on the NASDAQ at -2.1% below its 52-week average.


Investor Alert: Cassava Sciences, Inc. Faces Potential Legal Implications as Shareholders Are Urged to Take Action

Published Sat, Feb 17 2024 5:00 PM UTC

In a recent press release, global investor rights law firm Rosen highlights the critical importance for investors of Cassava Sciences, Inc. (NASDAQ: SAVA) to secure legal representation before the approaching lead plaintiff deadline of April 2, 2024. This deadline pertains to a securities class action against the company based on alleged wrongdoing during the Class Period, w...

Product Service News

Groundbreaking Two-Year Clinical Safety Study: Consistent Cognition Scores for Mild Alzheimer's Patients with Continuous Simufilam Treatment

Published Wed, Feb 7 2024 2:08 PM UTC

In an unprecedented development in the treatment of Alzheimer's disease, biotechnology firm Cassava Sciences, Inc. (Nasdaq: SAVA), reported top-line results from a two-year clinical safety study of Simufilam. This pioneering investigational oral drug is being proposed as a potential treatment for Alzheimer's disease dementia.The study, which enrolled over 200 patients diagno...


Cassava Sciences Inc Finalizes Warrant Distribution: A New Finance Chapter for Shareholders

Published Fri, Jan 5 2024 2:12 PM UTC

Austin, Texas-based biotech firm Cassava Sciences Inc. (Nasdaq: SAVA), has announced the successful completion of a previously announced distribution of warrants to its shareholders, taking a significant step in its corporate funding strategy. This move expands the company's capital base while offering investors a new opportunity for equity participation. These warrants...


Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

Published Tue, Dec 12 2023 2:13 PM UTC

AUSTIN, Texas, Dec. 12, 2023 - Cassava Sciences, Inc. (Nasdaq: SAVA) (Cassava Sciences or the Company) has exciting news for its shareholders. The Company recently announced a pro rata dividend distribution of warrants to holders of its common stock as of December 22, 2023, marking a significant step toward enhancing shareholder value.
Effective from the Record Date...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com